Skip to main content

Table 1 Patients’ baseline characteristics*

From: Effects of Ghrelin Treatment on Exercise Capacity in Underweight COPD Patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment

 

Ghrelin, n = 10

Placebo, n = 10

Age (years)

70.8 (6.4)

73.1 (5.6)

Sex (males/females)

10/0

9/1

BMI (kg/m2)

18.4 (2.4)

18.1 (2.3)

Cigarettes (pack-years)

59.1 (29.2)

64.8 (25.1)

Pulmonary function

  

FEV1 (L)

0.83 (0.21)

0.82 (0.23)

%FEV1 (% predicted)

32.0 (9.4)

33.3 (10.5)

FEV1/FVC (%)

41.7 (7.6)

42.4 (8.0)

VC (L)

2.54 (0.42)

2.62 (0.50)

%VC (%)

79.6 (11.0)

86.1 (15.3)

IC (L)

1.63 (0.22)

1.74 (0.38)

DLco (% predicted)

61.3 (23.8)

72.4 (27.4)

Exercise capacity in ICPET

  

Peak work rate (Watt)

36.0 (13.5)

34.0 (9.7)

Peak V • o 2 mL / kg / min

13.3 (3.7)

13.4 (3.2)

Medications

  

LAMA

7

5

SAMA

2

2

LABA

6

5

ICS

4

1

Methylxanthines

5

6

Comorbidity

  

Angina pectoris

2

0

PVC

0

1

  1. Data are presented as means (SD) unless otherwise stated. BMI Body mass index, DLco Carbon monoxide diffusing capacity, FEV 1 Forced Expiratory Volume in one second, FVC Forced Vital Capacity, IC Inspiratory Capacity, ICPET Incremental Cardiopulmonary Exercise Test, ICS Inhaled Corticosteroids, LABA Long-Acting β2-Agonist, LAMA Long-Acting Muscarinic Antagonist, PVC Premature Ventricular Contraction, SAMA Short-Acting Muscarinic Antagonist, VC Vital Capacity. * The groups shown represent all treated patients. Medications were not mutually exclusive, and data are presented separately.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us